Eris Lifesciences Limited Q1FY23 Revenues at INR 3,986 mn, up 14.1% YoY.
Commenting on the results, Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd., said,“The Oaknet business which we acquired in May 2022 is off to a strong start with Rs. 55 crore of revenue and Rs. 10 crore of EBIDTA in Q1 FY23. This looks like a sustainable run-rate through this year. We are looking at an exciting year ahead with a massive pipeline of new product launches in Q2 and Q3 of this year.”
Mr. Krishnakumar V, Executive Director & Chief Operating Officer of Eris Lifesciences Ltd., added, “We continue to be among the Top 10 fastest growing companies in the market. We are targeting a consolidated Revenue growth of 30% and EBIDTA growth of 16-17% in FY 23. This will be driven by a combination of growth in our power brands and new product launches in Cardio-Metabolic, Dermatology and Women’s Health.”